London, UK, 31 May 2007: Ark Therapeutics Group plc announces today that its
novel gene-based drug targeting platform technology, Scavidin(R), has shown
further pre-clinical evidence of being highly effective in slowing tumour
development and significantly improving survival time using a low dose of the
radiotherapy Yttrium90 which would be sub-therapeutic if administered
conventionally.
